May 8, 2018

Kybella

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Learn more about improving your chin profile NONSURGICALLY and PERMANENTLY by destroying the fat under your chin. Schedule a free, no-obligation consultation today!

What is KYBELLA?

KYBELLA is a prescription medicine used in adults to improve the appearance and profile of moderate to severe fat below the chin, also called “double chin.”

How Does It Work

  • Deoxycholic acid is a naturally occurring molecule that helps break down fat in the body.
  • The active ingredient in KYBELLA is synthetic deoxycholic acid.
  • Fat cells are broken down each time KYBELLA is injected into the treatment area beneath the chin.
  • Over a period of time, those cells are cleared away through the natural processes of your body.
  • Once the fat cells in the treatment area are gone, they’re GONE!!

What to Expect

  • Treat, repeat, complete – Dr. Lamb will recommend the number of treatment sessions you may need to achieve your goals.
  • Each treatment is at least 1 month apart – schedule your next visit before you leave the office.
  • Office staff will take your photo before and after each treatment – track the change in your chin profile line throughout your treatment series.
  • Injection process may take 15-20 minutes.

 

Common Side Effects

  • Swelling
  • Numbness
  • Redness
  • Pain
  • Areas of hardness

Possible Side Effects

  • Nerve injury in the jaw that can temporarily (median 44 days) cause an uneven smile or facial muscle weakness (experienced by 4 out of 100 patients in clinical studies).
  • Trouble swallowing (experienced by 2 out of 100 patients in clinical trials).
  • Possible injection side problems including bruising, hair loss, open sores (ulcers), and tissue damage and necrosis around the injection site.

 

 

KYBELLA® (deoxycholic acid) injection 10 mg/mL Indication and Important Safety Information

KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.

IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS

KYBELLA® is contraindicated in the presence of infection at the injection sites.

WARNINGS AND PRECAUTIONS

Marginal Mandibular Nerve Injury
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.

Dysphagia
Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.

Injection-Site Hematoma/Bruising
In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.

Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures
To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles.

Injection Site Alopecia
Cases of injection site alopecia have been reported with administration of KYBELLA®. Onset and duration may vary among individuals and may persist. Consider withholding subsequent treatments until resolution.

Injection Site Ulceration and Necrosis
Injections that are too superficial into the dermis may result in skin ulceration and necrosis. Cases of injection site ulceration and necrosis have been reported with administration of KYBELLA®. Do not administer KYBELLA® into affected area until complete resolution.

ADVERSE REACTIONS

The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.

Please see accompanying KYBELLA® full Prescribing Information.